Free Newsletter
New boilerplate pacts proposed for cancer projects
Academic researchers, hospitals and biotech companies are frequently forced to bring in expensive legal help to lay the framework for joint cancer research projects. But now the Justice Department has signed off on a plan to come up with boilerplate study contracts. And the National Cancer Institute is supporting the standard contracts.
J&J CEO and Chairman Bill Weldon told the Wall Street Journal that the contract negotiations over new development programs often create a "bottleneck" that slows the process down. So Weldon and other big developers are using the CEO Roundtable on Cancer to push the simplified legal approach. They came up with the standard contract after analyzing 75 existing contracts that bore remarkably similar language. This new approach could save up to a year of wasted efforts and delays.
- read the report from the Wall Street Journal
Related Articles:
NSF crunches the (eroding) numbers on academic R&D
Glaxo decides bigger is better for cancer research
Breakthrough points to new cancer drug class
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: